ATE122723T1 - Retinoblastoma-genprodukt-antikörper und deren verwendungen. - Google Patents

Retinoblastoma-genprodukt-antikörper und deren verwendungen.

Info

Publication number
ATE122723T1
ATE122723T1 AT90303297T AT90303297T ATE122723T1 AT E122723 T1 ATE122723 T1 AT E122723T1 AT 90303297 T AT90303297 T AT 90303297T AT 90303297 T AT90303297 T AT 90303297T AT E122723 T1 ATE122723 T1 AT E122723T1
Authority
AT
Austria
Prior art keywords
gene product
retinoblastoma gene
product antibodies
retinoblastoma
determining
Prior art date
Application number
AT90303297T
Other languages
English (en)
Inventor
Yuen Kai Fung
Ang Anne T
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of ATE122723T1 publication Critical patent/ATE122723T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736Retinoblastoma protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
AT90303297T 1989-03-31 1990-03-28 Retinoblastoma-genprodukt-antikörper und deren verwendungen. ATE122723T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33208289A 1989-03-31 1989-03-31

Publications (1)

Publication Number Publication Date
ATE122723T1 true ATE122723T1 (de) 1995-06-15

Family

ID=23296661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90303297T ATE122723T1 (de) 1989-03-31 1990-03-28 Retinoblastoma-genprodukt-antikörper und deren verwendungen.

Country Status (15)

Country Link
EP (1) EP0390530B1 (de)
JP (1) JPH04193900A (de)
KR (1) KR0175658B1 (de)
CN (1) CN1046759A (de)
AT (1) ATE122723T1 (de)
AU (1) AU638238B2 (de)
CA (1) CA2013544C (de)
DE (1) DE69019410T2 (de)
FI (1) FI901618A0 (de)
IE (1) IE63277B1 (de)
IL (1) IL93941A (de)
NO (1) NO179328C (de)
NZ (1) NZ233147A (de)
PT (1) PT93619A (de)
ZA (1) ZA902425B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118585A1 (en) * 1992-07-14 1994-01-20 H. Michael Shepard Characterization of a novel anti-p110rb monoclonal antibody
US5550020A (en) * 1994-07-08 1996-08-27 Visible Genetics Inc. Method, reagents and kit for diagnosis and targeted screening for retinoblastoma
US5545527A (en) 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
JP2000510330A (ja) * 1996-04-05 2000-08-15 トーマス・ジェファーソン・ユニバーシティ 癌の診断および予後のための方法
US5840506A (en) * 1996-06-05 1998-11-24 Thomas Jefferson University Methods for the diagnosis and prognosis of cancer
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
CN102053150B (zh) * 2009-10-30 2013-07-17 上海交通大学医学院附属瑞金医院 一种人成骨肉瘤干细胞相关抗原标记物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68928728T2 (de) * 1988-01-21 1998-12-10 Massachusetts Eye & Ear Infirmary, Boston, Mass. Diagnose von retinoblastoma

Also Published As

Publication number Publication date
IE901179L (en) 1990-09-30
CN1046759A (zh) 1990-11-07
PT93619A (pt) 1990-11-20
AU5246190A (en) 1990-10-04
EP0390530B1 (de) 1995-05-17
NO901461D0 (no) 1990-03-30
NO901461L (no) 1990-10-01
CA2013544C (en) 2001-02-06
IL93941A (en) 1995-03-30
CA2013544A1 (en) 1990-09-30
NZ233147A (en) 1993-04-28
DE69019410D1 (de) 1995-06-22
EP0390530A1 (de) 1990-10-03
DE69019410T2 (de) 1995-10-05
ZA902425B (en) 1991-01-30
AU638238B2 (en) 1993-06-24
KR900013987A (ko) 1990-10-22
JPH04193900A (ja) 1992-07-13
IL93941A0 (en) 1990-12-23
KR0175658B1 (ko) 1999-03-20
FI901618A0 (fi) 1990-03-30
IE63277B1 (en) 1995-04-05
NO179328C (no) 1996-09-18
NO179328B (no) 1996-06-10

Similar Documents

Publication Publication Date Title
GB9824632D0 (en) Biological compounds
ATE169640T1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
AU7074698A (en) Detection and modulation of the iaps and naip for the diagnosis and treatment ofproliferative disease
DK0733069T3 (da) Oprensede Primat CTLA-8-antigener og beslægtede reagenser
FI885543A (fi) Dna-segment, polypeptider och anti-kroppar anslutande till human vaevnadsfaktor.
DE69637148D1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
DE69833014D1 (de) Menschliche toll homologen
DE68925226D1 (de) Monoklonale Antikörper
AU585253B2 (en) Carrier material for use in immune determinations
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
CA2082382A1 (en) Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy
DE69839444D1 (de) Smad 6 und dessen anwendungen
FI885504A (fi) Vaskulaera antikoagulerande proteiner, dessa koderande dna, deras framstaellningsfoerfarande och deras anvaendning.
BR1100315A (pt) Processo para melhorar a imunogenicidade de um imunogênio ou de um hapteno, gene de fusão, vetor de dna, medicamento e utilização de um complexo entre um imunogênio e uma mólecula
DE68918217D1 (de) Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs.
ATE122723T1 (de) Retinoblastoma-genprodukt-antikörper und deren verwendungen.
NO970130L (no) Oligomere bærermolekyler med definerte, innebygde markörgrupper og haptener
MA26546A1 (fr) Composition pharmaceutique pour le traitement de la dysmenorrhee et les accouchements prematures.
ZA958038B (en) Isolated truncated nucleic acid molecules which code for gage tumor rejection antigen the tumor rejection antigen and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties